RÉSUMÉ
OBJECTIVE To provide information service support for research on proteolysis targeting chimera （PROTAC） in China and provide reference for technical development and patent layout of relevant drug research and development institutions. METHODS The patent analysis method was used to search the patent applications related to PROTAC technology that had been applied to China National Intellectual Property Administration and had been issued before Feb. 2022， using the HimmPat patent database as the search platform. The patent application trend， technology life cycle， main applicants， technology source countries， technology themes， improvement routes and other patent data were analyzed. RESULTS & CONCLUSIONS A total of 133 patents were included in this study. The patent application for PROTAC technology started relatively late in China， with the number of applicants increasing from 2 in 2015 to 30 in 2020， and the number of applications increasing from 2 in 2015 to 38 in 2020. Both the annual patent application volume and the number of applicants were in a period of rapid growth， but the average annual application volume of a single applicant was still less than 2， indicating that research in this field was still in the early stage of technology development； the number of applications from Arvinas， Hisco， and Hinova Pharmaceutical Inc. ranked among the top. Although the number of domestic applications led that of foreign applications in China， the average number of simple peer applications and the average number of simple peer countries in domestic patent applications was only 1.5， which was far lower than that of foreign applications in China， reflecting that there was still room for improvement in the “quality” level of domestic applications. The initial improvements in PROTAC technology mainly focused on the selection of E3 ligands， targets and ligands， and then new improvements such as new PROTAC development， linker design and matching methods emerged， indicating that the patent applicant had started a multi-track layout in the early stages of the development of PROTAC technology. It is suggested that the research and development of PROTAC drugs in China should focus on improving the oral bioavailability and biosafety of PROTAC drugs， overcoming potential drug resistance， and exploring rational design and evaluation methods.
RÉSUMÉ
There are a large number of patients with rare diseases in China, and most of them are faced with problems such as no medicine to cure, and have drugs outside of China but not inside. This paper combed the incentive policies of orphan drugs in the United States and the European Union, including orphan drugs legislation and setting up special management institutions, orphan drugs qualification certification, government funding, tax reduction and agreement assistance in the research and development process, providing accelerated listing channels in the examination and approval process, giving market monopoly period in the circulation stage, and giving priority to review. On this basis, it also explored the incentive measures of non-profit organizations in the research and development of orphan drugs, including providing financial support, clinical research and so on. From the perspective of guaranteeing the right to life and health of patients with rare diseases, the fairness and accessibility of medication, and the subjects’ right to know and privacy in clinical trials, this paper provides reference for perfecting the incentive mechanism of orphan drugs research and development in China.
RÉSUMÉ
Objective To investigate the quality and academic level of Traditional Chinese Drugs Research and Clinical Pharmacology by analyzing the cited articles.Methods Statistic Analysis and evaluation of citation of articles which were issued in Traditional Chinese Drugs Research and Clinical Pharmacology from the year of 2000 to 2004 and cited in the database of Chinese Biomedical Citation Index and the website of China Knowledge Information,was carried out by literature measurement method.Results There were 770 articles issued in Traditional Chinese Drugs Research and Clinical Pharmacology from the year of 2000 to 2004,the citation rate was 52.59 %,and the average citation frequency of each article was 3.22.There were a large amount of articles with high citation rate.The institutions of cited authors covered 27 provinces (including municipalities and autonomous regions ),special zones and countries,in which Guangdong,Beijing and Jiangsu provinces took the leading in the research of traditional Chinese medicine.The journal was cited by other 350 periodicals,and the citation rate was 93.72 %.The self-citation rate was 6.27 %.Conclusion The articles issued in Traditional Chinese Drugs Research and Clinical Pharmacolog have a high quality,and the journal is one of the most important information suppliers for the research of traditional Chinese drugs and clinical pharmacology and also a core journal for the development of new Chinese drugs and for the research of clinical pharmacology.